The role of ATM and 53BP1 as predictive markers in cervical cancer

Frank Roossink1*, Hylke W. Wieringa2*, Maartje G. Noordhuis1, Klaske A. ten Hoor1, Mirjam Kok1, Lorian Slagter-Menkema3,4, Harry Hollema3, Geertruida H. de Bock3, Elisabeth Pras6, Elisabeth G.E. de Vries2, Steven de Jong2, Ate G.J. van der Zee5, Ed Schuuring4, G. Bea A. Wisman1 and Marcel A.T.M. van Vugt2

1 Department of Gynaecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
2 Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
3 Department of Otolaryngology and Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
4 Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
5 Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
6 Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Key words: cervical cancer, response to (chemo)radiation, ATM pathway, resistance, DNA damage response

Abbreviations: AT: ataxia telangiectasia; ATM: ataxia telangiectasia mutated; DDR: DNA damage response; DSB: double-strand break; HPV: human papillomavirus; HR: hazard ratio; OR: odds ratio; p-ATM: phosphorylated ATM; p-53BP1: phosphorylated 53BP1; 53BP1: p53-binding protein-1; RPE: retinal pigment epithelium; Ser: serine; Thr: threonine

Additional Supporting Information may be found in the online version of this article.

*F.R. and H.W.W. contributed equally to this work.
Grant sponsor: The Netherlands Organization for Scientific Research (VENI Grant); Grant number: 916.76.062; Grant sponsor: The Dutch Cancer Society; Grant number: RUG 2007-3719
DOI: 10.1002/ijc.27488

History: Received 11 Jul 2011; Accepted 24 Jan 2012; Online 10 Feb 2012
Correspondence to: G. Bea A. Wisman, Department of Gynaecologic Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, E-mail: g.b.a.wisman@umcg.nl or Marcel A.T.M. van Vugt, Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, E-mail: m.vugt@umcg.nl

The standard of care for patients with advanced-stage cervical cancer has shifted over the last decade from radiotherapy alone to platinum-based chemoradiation.1 Despite the shift in this curative treatment modality, 5-year survival is still around 66%, which leaves ample room for improvement.2 Chemoradiation introduces high levels of DNA double-strand breaks (DSBs), with the aim to induce cell death.3,4 At the molecular level, cells respond to DNA breaks with the activation of a distinct pathway called the ‘DNA damage response’ (DDR). The DDR recognises DNA damage and subsequently coordinates a cell cycle arrest with the initiation of DNA repair.2,4 Counteracting the effects of the DDR might thus be an attractive option to improve treatment results in patients with advanced cervical cancer.

Central in the DDR is the ataxia telangiectasia-mutated (ATM) kinase. ATM plays a key role in detecting DNA DSBs and in coordinating DNA repair, cell cycle arrest and induction of apoptosis.4 When DNA DSBs are induced, ATM is activated through autophosphorylation on serine 1981 (Ser1981) and subsequently phosphorylates numerous downstream substrates, including cell cycle regulators, DNA repair factors and proteins involved in apoptosis.3,5,6 The
importance of ATM is underscored by the observed increased radiosensitivity and cancer incidence in patients with ataxia telangiectasia (AT), bearing a mutation in the ATM gene.\textsuperscript{7} One prototypical ATM substrate is the gene product of TP53-binding protein-1 (53BP1),\textsuperscript{8–11} originally identified as a protein that binds p53.\textsuperscript{12} In response to DNA damage, 53BP1 is rapidly phosphorylated by ATM on multiple residues including serine 25 (Ser25) and serine 1778 (Ser1778).\textsuperscript{6,13,14} Phosphorylated 53BP1 localises to irradiation-induced foci where it promotes the activation of p53 and Chk2 and mediates the recruitment of the repair factor BRCA1.\textsuperscript{8–10} 53BP1, like ATM, is also involved in the repair of DNA breaks by promoting non-homologous end joining.\textsuperscript{15,16} However, 53BP1 can also be detected on sites of homologous recombination and in addition influences this error-free type of repair.\textsuperscript{17} Altogether, these findings explain its important role in proper responses to DNA breaks, and many of the cellular defects observed in AT were recapitulated in 53BP1 knockout cells, including irradiation sensitivity, growth retardation and cancer predisposition.\textsuperscript{18,19}

The aim of our study was to investigate to which degree cervical cancer cells depend on the DDR after irradiation. For this purpose, we have analysed responses of a panel of cervical cancer cell lines to ionising irradiation. We have subsequently investigated the role of ATM and 53BP1 as potential targets for radiosensitising approaches \textit{in vitro}. Finally, we tested the predictive and prognostic properties of ATM pathway activity in tumours in a large, well-documented and consecutive series of patients with cervical cancer primarily treated with (chemo)radiation.

\textbf{Material and Methods}

\textbf{Cell-line studies}

The human papillomavirus (HPV)-positive cervical cancer cell lines HeLa, CaSki and SiHa (all p53 wt) as well as the HPV-negative C33A cell line (mutant p53) were cultured in DMEM:Ham’s F12 (1:1), supplemented with 10% of fetal calf serum, 100 U/ml of penicillin and 100 \textmu g/ml of streptomycin. Human embryonic 293T kidney cells, non-transformed human retinal pigment epithelial (RPE) cells and human BJ foreskin fibroblasts were cultured in DMEM, supplemented with 10% of fetal calf serum, 100 U/ml of penicillin and 100 \textmu g/ml of streptomycin. Authenticity of cell lines was verified by DNA short-tandem repeat analysis (Basetclear, Leiden, The Netherlands). If indicated, cells were transfected with pRetrosuper (pRS), pRS-53BP1#1 (targeting sequence 5’-GAACGAGGAGACGGTAATA-3’) or pRS-53BP1#2 (5’-GATACTGCTCATCAGT-3’) and with the packaging plasmids pMDG/P and pMDG in a 3:2:1 ratio using a calcium phosphate protocol. Virus-containing supernatant culture medium was filtered (0.22 \textmu m; Millipore, Billerica, MA), mixed with polybrene (4 \textmu g/ml) and used for infection for three consecutive 12-hr periods. Twenty-four hours after the third infection, puromycin was added (1 \textmu g/ml) for selection.

\textbf{Western blotting and immunofluorescence}

For Western blotting, cell lysates were obtained using Mammalian Protein Extraction Reagent (Thermo Scientific, Rockford, IL), supplemented with protease inhibitor and phosphatases inhibitor cocktail (Thermo Scientific, Etten-Leur, The Netherlands). Thirty micrograms of protein was used for SDS-PAGE. Separated proteins were transferred to Polyvinylidene fluoride membranes and blocked in 5% milk in tris-buffered saline-0.01% Tween20. Immunodetection was done with antibodies directed against 53BP1 (rabbit, H-300; Santa Cruz Biotechnology, Santa Cruz, CA), MDM-2 (mouse, AB1; Merck (Calbiochem), Darmstadt, Germany), phospho-Thr68-Chk2 (rabbit, C13C1; Cell Signaling Technology, Danvers, MA), p21 (Merck (Calbiochem), Darmstadt, Germany), \beta-actin (mouse, A5441; Sigma-Aldrich, St. Louis, MO) and phospho-Ser1981-ATM (rabbit, EP1890Y; Epitomics, Burlingame, CA). horseradish peroxidase-conjugated antibodies (DAKO Denmark A/S, Glostrup, Denmark) were used as secondary antibodies. Visualisation was performed using Enhanced Chemiluminescence (Lumilight, Roche diagnostics, Mannheim, Germany) and a Biorad Bioluminescence device, equipped with Quantity One/Chemidoc XRS software (Biorad, Veenendaal, The Netherlands).

For immunofluorescence, cells were grown on glass cover slips. One hour after treatment, cells were fixed in 3.7% formaldehyde, blocked in 5% bovine serum albumin and stained overnight using anti-53BP1 (rabbit, H-300; Santa Cruz Biotechnology, Santa Cruz, CA) and anti-\gamma-H2AX (mouse, mouse, Ser139, #05-636; Millipore, Billerica, MA). Cells were counterstained with Alexa-488- and Alexa-568-conjugated secondary antibodies. Visualisation was performed using Enhanced Chemiluminescence (Lumilight, Roche diagnostics, Mannheim, Germany) and a Biorad Bioluminescence device, equipped with Quantity One/Chemidoc XRS software (Biorad, Veenendaal, The Netherlands).

\textbf{Clonogenic survival assays}

Depending on the amount of irradiation, cells were seeded at 100 (0 Gy), 500 (2 Gy), 2,000 (4 Gy) or 5,000 cells per well (6 Gy) in six-well plates and allowed to adhere for 4 hr. Cells were subsequently irradiated at indicated doses. If indicated, cells were pre-treated with ATM inhibitor (KU55933, 10 \textmu M) for 30 min. ATM inhibitor (KU55933)-treated CaSki cells were seeded up to 80,000 cells per well due to extreme irradiation sensitivity observed in initial experiments. When colony size reached an approximate minimum size of 50 cells per
colonies after 10–14 days, were fixed and stained using methanol/acetic acid/water mixture (50, 20 and 30%, respectively), containing 0.01% Coomassie brilliant blue. Surviving fraction was calculated using the plating efficiencies, using the non-irradiated controls as a reference. Results shown are averages of three independent experiments performed in triplicate.

Apoptosis assays and proliferation measurements
Twenty-four hours after plating in six-well plates, cells were irradiated (10 Gy). If indicated, cells were pre-treated with ATM inhibitor (KU55933, 10 μM) for 30 min. Twenty-four hours after irradiation, apoptosis was assessed visually by fluorescence microscopy after staining nuclear chromatin with acridine orange. Apoptosis assays were independently performed in triplicate. To measure cell proliferation, 7,000 HeLa cells or SiHa cells were plated in 96-well plates in the presence or absence of KU55933 (10 μM). Directly after plating, or at 24, 48 or 72 hr after plating, 20 μl of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added for 2 hr. Subsequently, culture medium was removed, and then the cells were incubated in dimethyl sulfoxide for 30 min. Absorbance was measured at 520 nm using a Biorad microplate reader. Cell growth was measured by calculating relative increases of MTT conversion. MTT conversion at Day 1 of plating was used as a reference.

Flow cytometry
Cells were harvested at indicated time points after irradiation and fixed in ice-cold 70% ethanol. Cells were stained with rabbit anti-phospho-Ser10-Histone H3 antibody (rabbit, Cell Signaling Technology, Danvers, MA, #06570, 1:200) and subsequently stained with Alexa-488-conjugated anti-rabbit antibody (Invitrogen (Molecular Probes), Eugene, OR) and counterstained with propidium iodide/RNAse (Sigma-Aldrich, St. Louis, MO). Cell cycle distribution and phospho-Histone H3 positivity were analysed on a FACSCalibur (Becton Dickinson Biosciences, Franklin Lakes, NJ) equipped with CellQuest software. Per sample, at least $1 \times 10^4$ events were analysed, and indicated results show averages and standard deviations of three independent experiments.

Patients with cervical cancer
Immunohistochemical analysis was performed on pre-treatment tissue specimens of 375 patients with advanced-stage cervical cancer primarily treated with chemoradiation, collected between January 1980 and December 2006. Tissue specimens were used to generate a tissue microarray as described previously. Clinicopathological data of patients, analysed in this study, are summarised in Supporting Information Table S1. The mean follow-up time was 3.99 years (range: 0.1–18.3) for all patients. For patients who were still alive at the time of their final follow-up, the median follow-up time was 6.3 years. About 189 patients (50.4%) received only radiotherapy, whereas 186 (49.6%) patients received chemoradiation. Patients who received chemoradiation were younger compared to patients who received radiotherapy alone (median 46.8 vs. 64.8, p < 0.001). All other baseline characteristics were comparable in both groups (data not shown). Immunohistochemistry was performed with antibodies against phospho-Ser1981-ATM (rabbit, EP1890Y, S1981; Epitomics, Burlingame, CA), 53BP1 (rabbit, H-300, SC-22760; Santa Cruz Biotechnology, Santa Cruz, CA), phosphoSer25-53BP1 (rabbit, AB82559; Abcam, Cambridge, United Kingdom) and anti-γ-H2AX (mouse, #05-636; Millipore, Amsterdam, The Netherlands). As chemoradiation is associated with a better survival and is a time-dependent factor, we adjusted for treatment modality in the multivariate analyses. Additional detailed information about staining protocols, patient information, evaluation of stainings and statistical analysis can be found in the Supporting Information Document SD1.

Results
ATM- and 53BP1-dependent cell cycle arrest in response to irradiation
We investigated the role of ATM and 53BP1 in the cellular response to irradiation in cervical cancer cells. To study cell cycle arrest in G1 and G2 (a distinct early feature of the DDR), different doses of irradiation were tested for their ability to induce cell cycle arrest and foci formation of 53BP1 and γ-H2AX (Supporting Information Figs. S1A–S1D). To subsequently study the role of ATM and 53BP1 in these responses, we used chemical inhibition of ATM (KU55933) or interfered with the expression of 53BP1 using shRNA (Fig. 1a) in our panel of HPV-positive (SiHa, HeLa and CaSki) cell lines and the HPV-negative C33A cell line (harbouring a p53 mutant). Cell lines stably expressing 53BP1 shRNAs as well as cell lines in which ATM was inactivated showed normal proliferation compared to their control counterparts (Fig. 1b). Upon irradiation (5 Gy), clear cell cycle arrests in G1 and G2 were observed (Figs. 1b, 1d and 1e). Interestingly, ATM inhibition or 53BP1 depletion completely ablated the G1 arrest in response to irradiation in all examined HPV-positive cell lines (Figs. 1b and 1d). Similar results were obtained when we used a second shRNA against 53BP1 (Supporting Information Figs. S2A–S2C). These results indicate that both ATM and 53BP1 are required for the irradiation-induced G1 arrest in HPV-positive cervical cancer cell lines. The p53-mutant cell line C33A did not show a significant irradiation-induced G1 arrest (Fig. 1d), which is in line with the p53-dependent G1 arrest after irradiation. Indeed, neither ATM inhibition nor 53BP1 depletion further changed the proportion of G1 cells in C33A cells (Fig. 1d). We next investigated the ability of cervical cancer cells to arrest at the G2/M border. G2/M checkpoint activity was measured by the number of cells that enters mitosis after irradiation, judged by phospho-HistoneH3-positivity. Shortly after irradiation, control cells showed a clear decrease in the
percentage of mitotic cells, as expected from cells with an intact G2/M checkpoint (Figs. 1b and 1e). Notably, ATM inhibition resulted in failure to properly arrest cells at the G2/M border after irradiation (Figs. 1b and 1e). In sharp contrast, cells depleted of 53BP1 still exhibited a clear decrease in mitotic cells upon irradiation comparable to that of irradiated control cells (Figs. 1b and 1e). These results indicate that ATM, but not 53BP1, is required for a proper G2/M
arrest in response to irradiation, and furthermore, these results show that the G1 and G2/M arrests have different molecular requirements in cervical cancer cells.

Although previous studies have attributed an irradiation induced G1-arrest to p53 function, we still observed a prominent G1-arrest in all HPV-positive cervical cancer cell lines, despite the compromised p53 function in these cells. Therefore, we tested p53 function and observed expression of p53-target genes MDM2 and p21 in HeLa cells, albeit at low levels (Fig. 1c). Interestingly, depletion of 53BP1 resulted in a virtually complete loss of expression of MDM2 and p21, suggesting that the residual activity of p53 in cervical cancer cells depends on 53BP1 (Fig. 1c).

Regarding ATM inhibition as a therapeutic option, we compared the ability of ATM inhibition to induce apoptosis in HeLa cells versus human non-transformed RPE cells and human BJ foreskin fibroblasts. Although ATM inhibition clearly elevated the levels of apoptotic HeLa cells after irradiation, non-transformed RPE cells or BJ foreskin fibroblasts did not show any significant elevation of apoptosis levels in response to combined treatment with KU55933 and irradiation (Fig. 1f and Supporting Information Fig. S1E).

ATM, but not 53BP1, is required for clonogenic survival after irradiation

Our cell cycle analysis showed that ATM inhibition or loss of 53BP1 clearly led to different defects in response to irradiation (Fig. 1). Reduced ability to initiate cell cycle arrest in response to irradiation may also translate into altered survival kinetics of irradiated cells. To test this, we subsequently analysed clonogenic survival. To exclude that ATM inhibition resulted in altered growth rates and thereby influenced the results of the clonogenic survival assay upon irradiation, MTT proliferation assays were conducted and revealed that ATM inhibition on its own did not significantly alter growth rates of HeLa cells or SiHa cells (data not shown; Supporting Information Fig. S3A). Importantly, inhibition of ATM resulted in a dramatic reduction in clonogenic survival after...
irradiation, observed in all cell lines tested (Figs. 2a and 2b). Notably, CaSki cells appeared much more sensitive to ATM inhibition compared to other cell lines (Fig. 2b). In contrast, loss of 53BP1 only resulted in a very moderate loss of clonogenic survival after irradiation in all four cell lines (Figs. 2a and 2b). As expected, loss of 53BP1 did not further sensitize cells that were treated with ATM inhibitor (Figs. 2a and 2b).

Altogether, our results indicate a differential requirement for ATM or 53BP1 with respect to irradiation-induced cell cycle arrest and show that ATM inhibition dramatically radiosensitizes cervical cancer cells as judged by survival assays. These results imply that the levels of ATM activity, perhaps even prior to irradiation, may determine the effect of (chemo)radiation.

Predictive value of ATM and 53BP1 for response to treatment

To investigate the predictive value of ATM activity for response to irradiation in cervical cancer cells, we analysed the levels of phospho-Ser1981-ATM before and after irradiation (Fig. 3a). HeLa and SiHa cells have very low baseline levels of phospho-ATM, in contrast to CaSki cells that have activated ATM even prior to irradiation (Fig. 3a). Interestingly, baseline amounts of phospho-ATM seem to correlate with radioresistance, as CaSki cells were significantly more resistant to irradiation than HeLa and SiHa cells as observed in clonogenic survival assays (Fig. 3b). These findings suggest that ATM activity prior to treatment can be used as a predictor of response to irradiation. To test the specificity of antibodies in paraffin-embedded material, we analysed paraffin-embedded cervical cancer cell lines irradiated in the presence or absence of ATM inhibitors (Supporting Information Fig. S4A). Our results showed that irradiation clearly increases phospho-S1981-ATM levels as well as phospho-S25-53BP1 levels, a process that is completely reverted after pre-treatment with ATM inhibitor KU55933 (Supporting Information Fig. S4A). These findings indicate that phospho-S1981-ATM levels...
and phospho-S25-53BP1 can be detected specifically in paraffin-embedded cervical cancer cells and that both stainings reflect ATM activity.

To investigate whether indeed ATM activity has predictive value for response to (chemo)radiation, we examined phospho-Ser1981-ATM (phosphorylated ATM (p-ATM)) levels in pretreatment cervical cancer tissues. Representative p-ATM stainings in cervical cancer tissue are shown in Figure 3c (details of staining evaluation are described in Supporting Information Document SD1). Any positive nuclear staining (>10% of intensity) for p-ATM was observed in 344 of 349 patients (98.6%), indicating that ATM is activated at least to some degree in virtually all patients. High levels of p-ATM expression, however, were observed only in 183 patients (52.4%).

We analysed the expression levels of the ATM substrate 53BP1. Positive nuclear expression for 53BP1 was observed in 100% of the tumours with similar intensity, and thus, no statistical analysis for 53BP1 expression could be performed. Positive nuclear phospho-S25-53BP1 (phosphorylated 53BP1 (p-53BP1)) expression, representing ATM activity, was observed in 180 of 311 tumours (57.9%). As expected for a direct substrate of ATM,6,10,13 a positive signal for p-53BP1 was more frequently found in tumours with high p-ATM in comparison to negative/low p-ATM (odds ratio (OR) = 2.206; 95% CI = 1.383–3.519; p = 0.001).

We evaluated the relationship between clinicopathological data versus p-ATM and p-53BP1 expression (Table 1). Logistic regression analysis showed higher expression levels of p-ATM in advanced stage (≥IIb) tumours (OR = 1.851; p = 0.007). In addition, tumour diameter (≥4 cm; OR = 1.848; p = 0.014) and age (OR = 1.005; p = 0.006) were also related to p-ATM expression. None of the clinicopathological features showed a statistical relationship with positivity for p-53BP1 (Table 1).

Table 1. Relationship between tumour staining for p-ATM and p-53BP1 versus clinicopathological data

|                  | OR (95% CI) | p-value |
|------------------|-------------|---------|
| High p-ATM positive |             |         |
| Age              | 0.981 (0.968–0.994) | 0.006   |
| Stage ≥ IIb      | 1.851 (1.179–2.905) | 0.007   |
| Adenocarcinoma   | 1.778 (0.954–3.311) | 0.070   |
| Poor differentiation | 1.259 (0.799–1.983) | 0.321   |
| Lymphangio invasion | 0.715 (0.389–1.314) | 0.280   |
| Tumour diameter ≥ 4 cm | 1.848 (1.135–3.010) | 0.014   |
| p-53BP1 positive |             |         |
| Age              | 0.989 (0.975–1.004) | 0.168   |
| Stage ≥ IIb      | 1.253 (0.786–1.996) | 0.343   |
| Adenocarcinoma   | 0.764 (0.407–1.434) | 0.401   |
| Poor differentiation | 1.170 (0.724–1.891) | 0.521   |
| Lymphangio invasion | 0.724 (0.385–1.362) | 0.317   |
| Tumour diameter ≥ 4 cm | 1.118 (0.669–1.869) | 0.670   |

Table 2. Immunostaining in relation to poor response to therapy

|                  | Univariate | Multivariate1 |
|------------------|------------|---------------|
|                  | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Model I          |            |         |            |         |
| Age              | 1.009 (0.996–1.021) | 0.164 |            |         |
| Stage ≥ IIb      | 2.412 (1.449–4.015) | 0.001 | 2.337 (1.375–3.971) | 0.002 |
| Adenocarcinoma   | 1.700 (1.050–2.752) | 0.031 |            |         |
| Poor differentiation | 1.009 (0.669–1.521) | 0.967 |            |         |
| Lymphangio invasion | 0.946 (0.539–1.681) | 0.851 |            |         |
| Tumour diameter ≥ 4 cm | 2.210 (1.308–3.735) | 0.003 |            |         |
| High p-ATM positive | 1.817 (1.191–2.772) | 0.006 | 1.650 (1.076–2.528) | 0.022 |
| p-53BP1 positive | 1.083 (0.690–1.702) | 0.728 |            |         |
| Model II         |            |         |            |         |
| Age              | 1.014 (0.991–1.037) | 0.232 |            |         |
| Stage ≥ IIb      | 2.966 (1.292–6.810) | 0.010 | 3.462 (1.309–9.156) | 0.012 |
| Adenocarcinoma   | 4.621 (1.888–11.311) | 0.001 | 3.822 (1.430–10.214) | 0.007 |
| Poor differentiation | 0.852 (0.413–1.758) | 0.665 |            |         |
| Lymphangio invasion | 1.630 (0.694–3.827) | 0.262 |            |         |
| Tumour diameter ≥ 4 cm | 3.046 (1.196–7.760) | 0.020 |            |         |
| High p-ATM positive | 2.567 (1.243–5.299) | 0.011 | 2.336 (1.042–5.237) | 0.039 |
| p-53BP1 positive | 0.659 (0.305–1.423) | 0.289 |            |         |

1 Multivariate analysis adjusted for treatment modality. 2 Not in final step of multivariate analysis.
p-ATM and p-53BP1 in relation to response to (chemo)radiation and survival

To analyse the relationship of p-ATM and p-53BP1 protein expression with response to (chemo)radiotherapy, two models were used as described previously. In Model I, wherein treatment response is based on locoregional disease-free survival, 364 patients (97.1%) could be analysed. The evaluation of locoregional disease-free survival was used as it is a relevant measurement of local effects induced by (chemo)radiation, which induces ATM pathway activation. In this model, high p-ATM was related to poor locoregional disease-free survival in univariate Cox regression analysis [hazard ratio (HR) = 1.817; \( p = 0.006 \)] as well as in multivariate analysis (HR = 1.650; \( p = 0.022 \)), whereas p-53BP1 expression was not related (Table 2). Figure 3d depicts locoregional disease-free survival in relation to high p-ATM and p-53BP1 expression. In this analyses, the log-rank \( p \)-value for high p-ATM expression was \( p = 0.003 \). To further strengthen our hypothesis that high levels of p-ATM are associated to the response to (chemo)radiotherapy, we evaluated response-to-treatment in a second model. In Model II, we separated our data in two subsets of patients with the highest contrast in treatment response (see Patients and Methods section in Supporting Information Document SD1). In this model, a statistical significant association between high p-ATM and poor response to treatment was found in univariate logistic regression analysis (OR = 2.567; \( p = 0.011 \)) as well as in multivariate analysis (OR = 2.336; \( p = 0.039 \)) (Table 2). p-53BP1 was not related to response to (chemo)radiation. After selection of these extreme groups, the relationship of p-ATM with poor response-to-treatment was even stronger compared to Model I. These data indicate that pre-treatment ATM activity levels, but not phosphorylation status of 53BP1, is relevant for the response to (chemo)radiation in patients with cervical cancer.

Finally, we analysed the expression of p-ATM and p-53BP1 in relation to disease-specific survival. During follow-up, 201 of 375 (201/375 = 54%) patients died. In 155/201 = 77% of these patients, death was related to cervical cancer (disease-specific survival). In line with our results described above, no relationships were observed between p-53BP1 expression and disease-specific survival. However, we found that high p-ATM expression was related to worse disease-specific survival (HR = 1.418; \( p = 0.038 \)) in univariate analysis (Table 3), again underscoring a role for ATM activity in cervical cancer behaviour.

Discussion

Our study shows a critical role for active ATM in the response of cervical cancer to irradiation, both in cervical cancer cell lines as well as in patients with cervical cancer treated with (chemo)radiation. Our \textit{in vitro} studies indicate that cervical cancer cells, even in the presence of HPV E6 expression, which blocks p53 function, still undergo a robust G\(_1\) cell cycle arrest in response to irradiation. HPV-positive cervical cancer cells require both ATM activity and the presence of 53BP1 for induction of this irradiation-induced G\(_1\) arrest. In addition, ATM, but not 53BP1, is required for induction of a G\(_2\)/M cell cycle arrest.

The requirements for ATM and 53BP1 for induction of an irradiation-induced G\(_1\) arrest are likely explained by residual p53 function in HPV-positive cervical cancer cells, which most often carry wild-type alleles of p53. Both ATM and 53BP1 have been described to regulate p53 function. Although ATM has been extensively described to directly regulate p53,\(^4\) a role for 53BP1 in the regulation of p53 is controversial. 53BP1 was initially demonstrated to bind p53 and promote p53 activity\(^,\)\(^2\), however, T-cells from 53BP1\(^{-/-}\) mice still showed robust irradiation-induced p53 responses. Our results indicate that 53BP1 is required for p53 function, albeit in a background with compromised p53 levels. However, in HPV-positive cervical cancer cells this does not appear to have functional consequences, since 53BP1-depletion did not dramatically alter clonogenic survival of cell lines after irradiation. Moreover, 53BP1-phosphorylation was not associated with response to (chemo)radiation.

In our study, the inhibition of ATM in cervical cancer cells interfered with the irradiation-induced G\(_1\) and G\(_2\)/M cell cycle arrest, in line with the loss of checkpoint function in cells from patients with AT.\(^4,\)^\(^7\)\(^3\)\(^0\) ATM inhibition
Furthermore severely decreased clonogenic survival for all tested cervical cancer cell lines, indicating that cervical cancer cells heavily depend on the ATM signalling axis for survival after irradiation. Interestingly, when ATM was inhibited in irradiated non-transformed RPE cells or BJ foreskin fibroblasts, no induction of apoptosis was observed, in contrast to the apoptotic effects of ATM inhibition on HeLa cells, implying that a therapeutic window for ATM inhibition may be present. Further research, however, is required to investigate the long-term toxicity profile of ATM inhibition in normal cells. In addition, investigation of the combined effects of radiotherapy and ATM inhibition in normal tissues are needed to further establish ATM as a therapeutic target for radiosensitisation.

These observations, as well as our findings that high baseline levels of active ATM correlate to increased clonogenic survival after irradiation, suggest that high levels of activated ATM levels are beneficial for cervical tumour cell survival. Previously, it has been acknowledged that the ability to repair therapy-induced DNA damage counteracts the efficacy of therapy in a number of tumour types. For instance, high expression levels of the repair enzyme MGMT counteracts therapy-induced DNA damage in gliomas. Conversely, low expression level of the DNA damage repair gene ERCC1 correlates with prolonged survival of gliomas. The diversity of these results could be explained by differences in treatment modality between and even within these studies. Moreover, our study focussed predominantly on the activation status of both proteins, rather than expression levels only. Finally, carcinogenesis of cervical cancer is fundamentally different from that of the tumour types under study in the latter reports. It may very well be that early inactivation of p53 through HPV infection account for differences in prognostic factors, especially those functioning within the DDR.

ATM is activated in response to chemoradiation. The relatively high levels of p-ATM that we observed in our therapy-naive cervical tumour specimens could represent continuous activation of the ATM-regulated DDR as a result of deregulated proliferation, as also reported for other tumour types. Alternatively, elevated levels of p-ATM prior to (chemo)radiation may point at DNA damage-independent functions of ATM, such as the recently reported role for ATM in sensing oxidative stress levels.

In summary, on the basis of our results, high phospho-ATM levels is an independent predictor for poor response in cervical cancer. In addition, targeting ATM kinase activity could be an interesting therapeutic option to sensitize tumour cells for (chemo)radiation in patients with cervical cancer who have high tumour levels of active ATM before start of (chemo)radiotherapy. Our data, in line with other reports, show that inhibition of ATM by targeted drug application results in enhanced sensitivity to radiotherapy, recapitulating the radiosensitivity phenotypes of cells of patients with AT. Moreover, in short-term in vitro assays, a therapeutic window for ATM inhibition appears to be present for ATM inhibition when the toxicity to non-cancer cells is taken into account. This differential sensitivity to ATM inhibition may be related to HPV-dependent rewiring of the cell cycle machinery. Other investigations have reported enhanced radiosensitivity by inhibition of ATM in several malignancies. Although ATM inhibitors are still in preclinical development, our study suggests relevance of ATM-targeted agents and warrants a further assessment of ATM inhibition as a (chemo)radiosensitising treatment in patients with advanced-stage cervical cancer. However, besides increased radiosensitivity, patients with AT also show increased cancer development, and therefore, prolonged ATM inhibition should be avoided. In clinical settings, only a scenario in which short-term ATM inhibition can be combined with the local induction of DNA damage seems feasible. In this respect, it is very relevant that reversible ATM inhibitors have recently been described and that transient ATM inhibition was shown to reach radiosensitising effects in cancer cells.
Roossink et al. 2065

References

1. Rose PG. Chemoradiotherapy for cervical cancer. Eur J Radiol. 2002;43:278–84.
2. Vale CJT, Stewart LA, Brady M, Dinshaw K, Jakobsen A, Parmar MK, Thomas G, Trimble T, Alberts DS, Chen H, Cikaric S, Efiel PJ, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:802–12.
3. Kastan MB, Bartek J. Cell cycle checkpoints and cancer. Nature. 2004;432:316–23.
4. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3:155–68.
5. Bakkenist CJ, Kastan MB. DNA damage activates DNA damage. Nat Rev Mol Cell Biol. 2000;1:550–62.
6. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Koonin EV, et al. ATM-dependent DNA damage checkpoint function is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol. 2003;23:2556–63.
7. van Vught MA, Gardino AK, Linding R, Osnehmer GJ, Reinhardt HC, Ong SE, Tan CS, Miao H, Keezer SM, Li J, Penson T, Lewis TA, et al. A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G2/M DNA damage checkpoint. PLoS Biol. 2010:e1000287.
8. Rappold I, Iwabuchi K, Date T, Chen J. Tumor suppressor p53 binding protein 1 (53BP1) is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol. 2003;23:2556–63.
9. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. Accumulation of checkpoint protein 53BP1 at double-strand breaks. J Cell Biol. 2001;153:613–20.
10. Luo Y, Roosbroek M, Kolluri R, Jiang S, Shi W, Meng Y, et al. Human p53 is a cell cycle checkpoint sensor for DNA damage. Science. 2009;325:155–68.
11. Xia Z, Morales JC, Dunphy WG, Carpenter PB. 53BP1 promotes non-homologous end joining of DNA double strand breaks. DNA Repair (Amst). 2006;5:741–9.
12. Bouwman P, Aly A, Escandell JM, Pietere T, Bartkova J, van der Golden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Halaffy BG, Tommiska J, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17:688–95.
13. Fernandez-Capetillo O, Chen HT, Celeste A, Ward I, Romanenko PJ, Morales JC, Naka K, Xia Z, Camerini-Otero RD, Motoyama N, Ward I, Romanienko PJ, Morales JC, Naka K, Xia Z, Camerini-Otero RD, Motoyama N, Carpenter PB, Bonner WM, et al. DNA damage-induced G2-M checkpoint arrest by histone H2AX and 53BP1. Nat Cell Biol. 2002;4:993–7.
14. Ward IM, Minn K, van Deursen J, Chen J. p53 binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol. 2003;23:2556–63.
15. van Vught MA, Gardino AK, Linding R, Osnehmer GJ, Reinhardt HC, Ong SE, Tan CS, Miao H, Keezer SM, Li J, Penson T, Lewis TA, et al. A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G2/M DNA damage checkpoint. PLoS Biol. 2010:e1000287.
16. Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, Hollema H, Mom CH, de Bock GH, Wisman GB, Schuuring E, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGF R predictor poor response to (chemo)radiotherapy and survival in cervical cancer. Clin Cancer Res. 2009;15:7389–97.
17. Hickson I, Zhao Y, Richardson CJ, Shiloh Y, Fields S. Stimulation of p53-mediated transcriptional activation by the p53-binding protein 1 (53BP1) is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol. 2003;23:2556–63.
18. Rappold I, Iwabuchi K, Date T, Chen J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol. 2001;153:613–20.
19. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. Accumulation of checkpoint protein 53BP1 at double-strand breaks. J Cell Biol. 2001;153:613–20.
20. Wang B, Matsuoka S, Carpenter PB, Elledge SJ. 53BP1, a mediator of the DNA damage checkpoint. Science. 2002;298:1435–8.
21. Xia Z, Morales JC, Dunphy WG, Carpenter PB. Negative cell cycle regulation and DNA damage-inducible phosphorylation of the BRCT protein 53BP1. J Biol Chem. 2001;276:2708–18.
22. Iwabuchi K, Bartkova J, Liu B, Marraccini R, Fields S. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA. 1994;91:6908–10.
23. Joys C, Mroric NA, Hastie CJ, McLauchlan H, Toth R, Roue J. Characterisation of the sites of DNA damage-induced 53BP1 phosphorylation catalysed by ATM and ATR. DNA Repair (Amst). 2007;6:35–46.
24. Ward IM, Minn K, Jorda KG, Chen J. Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to polyamine histone H2AX. J Biol Chem. 2003;278:19579–82.
25. Dimitrova N, Chen YC, Spector DL, de Lange T. 53BP1 promotes non-homologous end joining of telomeres by increasing chromatin mobility. Nat Struct Mol Biol. 2006;13:556–8.
26. Nakamura K, Sakai W, Kawamoto T, Bree RT, Lowndes NF, Takeda S, Taniguchi Y. Genetic dissection of vertebrate 53BP1: a major role in non-homologous end joining of DNA double strand breaks. DNA Repair (Amst). 2006;5:741–9.

Nussenzweig A, Chen J. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol. 2005;25:10079–86.
27. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Forneke AJ. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992;71:587–97.
28. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–4.
29. Lord RV, Brabender J, Gandara D, Albero V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez J, Danenberg KD, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286–91.
30. Yu G, Zhu MH, Zhu Z, Ni CR, Zheng JM, Li FM. Expression of ATM protein and its relationship with p53 in pancreatic carcinoma with tissue array. Pancreas. 2004;28:421–6.
31. Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, Gabbett HE, Quirke P, Mueller W. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res. 2006;12:1494–500.
32. Soderlund K, Stal O, Skog L, Rutqvist LE, Nordenskold B, Askmalms M. Intact Mre11/ Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:50–8.
33. Sarbia M, Ott N, Puhringer-Oppermann F, Brucher BL. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in early human tumorigenesis. OMICS. 2009;13:345–54.
34. Pan S, Cheng L, White JT, Lu W, Uleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B. Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS. 2009;13:345–54.
35. Bartkova J, Horejzi Z, Koed K, Kramer A, Tort F, Zieger K, Goldberg P, Sehested M, Nesland JM, Lukas C, Ortufo T, Lukas J, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–70.
36. DiTullio RA, Jr, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, Halazonetis TD. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol. 2002;4:998–1002.
37. Guo Z, Kozlov S, Lavin MF, Person MD, Paull T. ATM activation by oxidative stress. Science 2010;330:517–21.

Int. J. Cancer. 131, 2056–2066 (2012) © 2012 UICC
42. Fuhrman CB, Kilgore J, LaCoursiere YD, Lee CM, Milash BA, Soisson AP, Zempolich KA. Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition. Gynecol Oncol 2008;110:93–8.

43. Li W, Jian W, Xiaoping X, Yingfeng L, Tao X, Xiaoyan X. Enhanced radiation-mediated cell killing of human cervical cancer cells by small interference RNA silencing of ataxia telangiectasia-mutated protein. Int J Gynecol Cancer 2006;16:1620–30.

44. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987;316:1289–94.

45. Cowell IG, Durkacz BW, Tilby MJ. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectasia mutated. Biochem Pharmacol 2005;71:13–20.

46. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Meneur KA, O’Connor MJ, Povirk LF, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 2009;8:2894–902.

47. Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008;68:7466–74.

48. Roy K, Wang L, Makrigiorgos GM, Price BD. Methylation of the ATM promoter in glioma cells alters ionizing radiation sensitivity. Biochem Biophys Res Commun 2006;344:821–6.

49. Zou J, Qiao X, Ye H, Zhang Y, Xian J, Zhao H, Liu S. Inhibition of ataxia-telangiectasia mutated by antisense oligonucleotide nanoparticles induces radiosensitization of head and neck squamous-cell carcinoma in mice. Cancer Biother Radiopharm 2009;24:339–46.